Compare AAME & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | FEMY |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | United States |
| Employees | 156 | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 51.5M |
| IPO Year | N/A | 2021 |
| Metric | AAME | FEMY |
|---|---|---|
| Price | $2.44 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 27.6K | ★ 1.9M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 11.99 | ★ 63.53 |
| 52 Week Low | $1.25 | $0.31 |
| 52 Week High | $3.71 | $1.80 |
| Indicator | AAME | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 53.08 |
| Support Level | $2.34 | $0.79 |
| Resistance Level | $2.62 | $0.91 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 21.64 | 34.37 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.